S 312 | CAS#120004-07-1 | antagonist

MedKoo Cat#: 585131 | Name: S 312

Description:

WARNING: This product is for research use only, not for human or veterinary use.

S 312 is a calcium antagonist.

Chemical Structure

S 312

CAS#120004-07-1

Theoretical Analysis

MedKoo Cat#: 585131

Name: S 312

CAS#: 120004-07-1

Chemical Formula: C20H22N2O4S

Exact Mass: 386.1300

Molecular Weight: 386.47

Elemental Analysis: C, 62.16; H, 5.74; N, 7.25; O, 16.56; S, 8.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

S 312; S312; S-312

IUPAC/Chemical Name

Thieno(2,3-b)pyridine-5-carboxylic acid, 4,7-dihydro-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-, methyl ester, (+-)-

InChi Key

UTLPUICHKZBRCI-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H22N2O4S/c1-11(2)8-14-10-27-19-18(14)17(16(12(3)21-19)20(23)26-4)13-6-5-7-15(9-13)22(24)25/h5-7,9-11,17,21H,8H2,1-4H3

SMILES Code

O=C(C1=C(C)NC2=C(C(CC(C)C)=CS2)C1C3=CC=CC([N+]([O-])=O)=C3)OC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 386.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mihara S, Fujimoto M. Effect of S-312, a new calcium channel blocker, on the 1,4-dihydropyridine binding sites in porcine basilar blood vessels and rat aortic smooth muscle cells. Jpn J Pharmacol. 1991 Jul;56(3):249-59. PubMed PMID: 1832726. 2: Gunderson J, Masland S, Choi-Kain L. Good psychiatric management: a review. Curr Opin Psychol. 2018 Jun;21:127-131. doi: 10.1016/j.copsyc.2017.12.006. Epub 2018 Jan 5. Review. PubMed PMID: 29547739. 3: Gemba T, Ninomiya M, Matsunaga K, Ueda M. Effects of a novel calcium antagonist, S-(+)-methyl-4,7-dihydro-3-isobutyl-6- methyl-4-(3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate (S-312-d), on ischemic amino acid release and neuronal injury in stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther. 1993 Apr;265(1):463-7. PubMed PMID: 8474028. 4: Ninomiya M, Tani T, Nakajima S, Ueda M. Effects of S-312, a new calcium antagonist, on the mechanical and electrophysiological responses of isolated cardiovascular preparations. Jpn J Pharmacol. 1989 Oct;51(2):227-38. PubMed PMID: 2593380. 5: Yagami T, Ueda K, Sakaeda T, Itoh N, Sakaguchi G, Okamura N, Hori Y, Fujimoto M. Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65. PubMed PMID: 15006551. 6: Shimizu T, Kawabata T, Nakamura M. Protective effect of a novel calcium blocker, S-312-d, on ischemic acute renal failure in rat. J Pharmacol Exp Ther. 1990 Nov;255(2):484-90. PubMed PMID: 2243338. 7: Ueda M, Masui M, Kawakami M, Matsunaga K, Gemba T, Ninomiya M, Nakano A, Torii M, Adachi I, Ito H. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 4th communication: prophylactic and therapeutic effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3- b]pyridine-5-carboxylate in stroke-prone spontaneously hypertensive rats. Arzneimittelforschung. 1993 Dec;43(12):1291-303. PubMed PMID: 8141816. 8: Amano T, Aihua Z, Matsubayashi H, Seki T, Serikawa T, Sasa M, Sakai N. Antiepileptic effects of single and repeated oral administrations of S-312-d, a novel calcium channel antagonist, on tonic convulsions in spontaneously epileptic rats. J Pharmacol Sci. 2004 Jul;95(3):355-62. PubMed PMID: 15272212. 9: Eigyo M, Shiomi T, Inoue Y, Sakaguchi I, Ishibashi C, Murata S, Koyabu K, Matsushita A, Adachi I, Ueda M. Pharmacological studies on a new dihydrothienopyridine calcium antagonist, S-312-d. 5th communication: anticonvulsant effects in mice. Jpn J Pharmacol. 1994 Jun;65(2):175-7. PubMed PMID: 7967231. 10: Nakajima M, Adachi I, Ueda M. Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey. Arzneimittelforschung. 1993 Dec;43(12):1276-82. PubMed PMID: 8141814. 11: Nakano H, McCormick DB. Stereospecificity of the metal.ATP complex in flavokinase from rat small intestine. J Biol Chem. 1991 Nov 25;266(33):22125-8. PubMed PMID: 1657990. 12: Ueda M, Matsumura S, Masui M, Matsuura E, Kawakami M, Fujitomo H, Umeda T, Kagawa H, Hirohata S, Shima K, et al. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs. Arzneimittelforschung. 1993 Dec;43(12):1282-90. PubMed PMID: 8141815. 13: Ueda M, Matsumura S, Masui M, Matsuura E, Uno O, Kawakami M, Ninomiya M, Adachi I. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 1st communication: comparative studies on the cardiovascular effects of methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3- b]pyridine-5-carboxylate and its two enantiomers in experimental animals. Arzneimittelforschung. 1993 Dec;43(12):1270-5. PubMed PMID: 8141813. 14: Keuroghlian AS, Gunderson JG, Pagano ME, Markowitz JC, Ansell EB, Shea MT, Morey LC, Sanislow C, Grilo CM, Stout RL, Zanarini MC, McGlashan TH, Skodol AE. Interactions of borderline personality disorder and anxiety disorders over 10 years. J Clin Psychiatry. 2015 Nov;76(11):1529-34. doi: 10.4088/JCP.14m09748. PubMed PMID: 26114336. 15: Patel NC, Palmer WC, Gill KR, Cangemi D, Diehl N, Stark ME. Changes in efficiency and resource utilization after increasing experience with double balloon enteroscopy. World J Gastrointest Endosc. 2013 Mar 16;5(3):89-94. doi: 10.4253/wjge.v5.i3.89. PubMed PMID: 23515876; PubMed Central PMCID: PMC3600554. 16: Tanaka H, Mizojiri K. Drug-protein binding and blood-brain barrier permeability. J Pharmacol Exp Ther. 1999 Mar;288(3):912-8. PubMed PMID: 10027826. 17: Waller R, Murphy M, Garwood CJ, Jennings L, Heath PR, Chambers A, Matthews FE, Brayne C, Ince PG, Wharton SB, Simpson JE; Cognitive Function and Ageing Neuropathology Study Group. Metallothionein-I/II expression associates with the astrocyte DNA damage response and not Alzheimer-type pathology in the aging brain. Glia. 2018 Nov;66(11):2316-2323. doi: 10.1002/glia.23465. Epub 2018 Aug 10. PubMed PMID: 30098078. 18: Yasui M, Kawasaki K. Vulnerability of CA1 neurons in SHRSP hippocampal slices to ischemia, and its protection by Ca2+ channel blockers. Brain Res. 1994 Apr 11;642(1-2):146-52. PubMed PMID: 8032875. 19: Dessy C, Salomone S, Morel N, Godfraind T. Activity of dihydrothienopyridine S312 enantiomers on L-type Ca2+ channels in isolated rat aorta and cerebral microvessels. Eur J Pharmacol. 1993 Feb 16;231(3):435-42. PubMed PMID: 8449235. 20: Jizomoto H, Kanaoka E, Sugita K, Hirano K. Gelatin-acacia microcapsules for trapping micro oil droplets containing lipophilic drugs and ready disintegration in the gastrointestinal tract. Pharm Res. 1993 Aug;10(8):1115-22. PubMed PMID: 8415395.